Chiang Chih-Chao, Korinek Michal, Cheng Wei-Jen, Hwang Tsong-Long
Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Puxin Fengze Chinese Medicine Clinic, Taoyuan, Taiwan.
Front Pharmacol. 2020 Oct 9;11:572009. doi: 10.3389/fphar.2020.572009. eCollection 2020.
This review describes targeting neutrophils as a potential therapeutic strategy for acute respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID-19), a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutrophil counts are significantly elevated in patients with COVID-19 and significantly correlated with disease severity. The neutrophil-to-lymphocyte ratio can serve as a clinical marker for predicting fatal complications related to ARDS in patients with COVID-19. Neutrophil-associated inflammation plays a critical pathogenic role in ARDS. The effector functions of neutrophils, acting as respiratory burst oxidants, granule proteases, and neutrophil extracellular traps, are linked to the pathogenesis of ARDS. Hence, neutrophils can not only be used as pathogenic markers but also as candidate drug targets for COVID-19 associated ARDS.
本综述描述了将中性粒细胞作为2019冠状病毒病（COVID-19）相关急性呼吸窘迫综合征（ARDS）的一种潜在治疗策略，COVID-19是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的大流行病。COVID-19患者的中性粒细胞计数显著升高，且与疾病严重程度显著相关。中性粒细胞与淋巴细胞的比例可作为预测COVID-19患者ARDS相关致命并发症的临床标志物。中性粒细胞相关炎症在ARDS中起关键的致病作用。中性粒细胞作为呼吸爆发氧化剂、颗粒蛋白酶和中性粒细胞胞外陷阱的效应功能与ARDS的发病机制有关。因此，中性粒细胞不仅可作为致病标志物，还可作为COVID-19相关ARDS的候选药物靶点。
